Outcomes of Human Papilloma Virus Vaccination in a Private Women Health Clinic in Lebanon

Table 4

Time to recurrence of CIN lesions following treatment of CIN2+ or detection of <CIN2 in women who received the human papilloma virus vaccine at the Women’s Health Center (WHC) of the American University of Beirut-Medical Center (AUBMC) 2007–2017.

Recurrence time for CIN2+ and <CIN2+		value
NS2 group (n = 4)	37.6 ± 15	0.50
^+SA group (n = 6)	30.1 ± 18

NS2: not previously sexually active at the time of first dose of vaccination; +SA: sexually active before first dose of vaccination.